Intelligence Feed event · Equity · 2026-10-10

    DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS Growth

    Question

    DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS Growth

    Direct answer

    DaVita HealthCare closed at $179.25, gaining 1.26% as investors positioned ahead of upcoming earnings. The dialysis provider is expected to generate 50.60% EPS growth for the quarter alongside 3.23% revenue growth. Full-year earnings expansion is forecast at 35.16%. The equity currently trades at a forward P/E multiple of 12.15, offering defensive healthcare cash flows amid broader market valuation concerns.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-10
    Published
    2026-10-20
    Revision
    1 · 2026-10-21

    Cite as: Market Ontology, “DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS Growth”, revision 1, evidence through 2026-10-10. https://marketontology.com/market-events/2026-10-10/davita-outpaces-s-p-500-on-forecast-50-6-percent-quarterly-eps-growth-78c7a6

    EQUITY
    DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS Growth
    DaVita HealthCare closed at $179.25, gaining 1.26% as investors positioned ahead of upcoming earnings. The dialysis provider is expected to generate 50.60% EPS growth for the quarter alongside 3.23% revenue growth. Full-year earnings expansion is forecast at 35.16%. The equity currently trades at a forward P/E multiple of 12.15, offering defensive healthcare cash flows amid broader market valuation concerns.
    DVASPY
    Impact
    61
    OCT 10
    SIG
    85%
    DVASPY
    DaVita Outpaces S&P 500 on Forecast 50.6 Percent Quarterly EPS Growth
    DaVita HealthCare closed at $179.25, gaining 1.26% as investors positioned ahead of upcoming earnings. The dialysis provider is expected to generate 50.60% EPS growth for the quarter alongside 3.23% revenue growth. Full-year earnings expansion is forecast at 35.16%. The equity currently trades at a forward P/E multiple of 12.15, offering defensive healthcare cash flows amid broader market valuation concerns.
    → Improving treatment volume economics and operational cost containment expand DaVita's operating margin, attracting value re-allocation at a 12.15 forward P/E multiple.
    Impact
    DaVita HealthCare closed at $179.25, gaining 1.26% as investors positioned ahead of upcoming earnings. The dialysis provider is expected to generate 50.60% EPS growth for the quarter alongside 3.23% revenue growth. Full-year earnings expansion is forecast at 35.16%. The equity currently trades at a forward P/E multiple of 12.15, offering defensive healthcare cash flows amid broader market valuation concerns.
    Affected
    DVASPY
    Transmission
    Improving treatment volume economics and operational cost containment expand DaVita's operating margin, attracting value re-allocation at a 12.15 forward P/E multiple.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    DVAmargin recovery driving valuation rerating toward healthcare sector mediansUp1-4wDVA closed at $179.25, up 1.26%, with full-year EPS growth projected at 35.16% and forward P/E at 12.15.
    SPYdefensive healthcare service multiple supportUp1-5dDVA outpaced the S&P 500's 0.60% gain.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    SPYUpdisagreed778.57 2026-10-09-0.06%-1.97%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month